| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 9.74 | 1.3% | 4.0% |
| Total Income | 9.74 | 1.3% | 4.0% |
| Expenditure | 10.02 | 6.7% | 21.2% |
| PBT | — | ||
| Net Profit | -0.68 | 52.8% | 164.2% |
| OPM | -2.88% | 8.81pp | 21.37pp |
| NPM | -7.00% | 7.96pp | 17.40pp |
| EPS | -0.08 | 52.9% | 166.7% |
Sanuwave Health Reports Preliminary Q2 2026 Revenue of $9.6-$9.8 Million
14 Jul 2026 · 14 Jul, 2:11 am
Summary
Sanuwave Health announced preliminary, unaudited revenues for the second quarter of 2026 are expected to be in the range of $9.6 million to $9.8 million, surpassing the high end of its revised guidance. This represents a slight decrease of approximately 3-5% compared to $10.1 million in the second quarter of 2025. CEO Morgan Frank noted that while capital sales faced headwinds, sales of consumable applicators reached record highs for both unit sales and revenues, indicating growing confidence in Ultramist as a wound care modality and a promising trend for the future.
Key Highlights
- 1
Sanuwave Health announced preliminary, unaudited revenues of $9.6 million to $9.8 million for the second quarter ended June 30, 2026, exceeding the high end of the Company’s revised guidance.
- 2
Preliminary second quarter revenues are expected to represent a decrease of approximately 3–5% from revenues of $10.1 million in the second quarter of 2025.
- 3
Sales of consumable applicators set all-time records for both unit sales and revenues in the second quarter.
- 4
The company is working to help qualify, train, and support new users of used Ultramist systems and offering attractive trade-in terms for certified pre-owned systems.
Management Comments
Morgan Frank
Q2 came in a bit above the top of the range that we laid out back in June. The business played out largely as we had forecast with capital sales facing headwinds from stress in our customer base and from the sale of used Ultramist systems in our market. Regarding the latter, as we discussed in our last release, Sanuwave will always seek to do what’s best for the patients, so we’ve been working to help qualify, train, and support such new users and offering attractive trade-in terms such that units purchased used can be traded in for certified pre-owned systems that would carry a manufacturer’s warranty. This program has been showing success so far. The good news in the quarter is that sales of consumable applicators set all time records for both unit sales and revenues, both by significant margins. We see this as an indication of both increasing interest and confidence in Ultramist as a wound care modality and, obviously, as consumables are the core of any razor-razorblade business, as a promising trend for the future. We look forward to speaking with you more about this when the Company reports Q2 earnings in August.
Informational and educational content only. Not investment advice.